Fibroblast proliferation promotion

Fibroblast proliferation promotion refers to various molecular pathways and extracellular signals that stimulate fibroblast cell division and expansion. This process is regulated by major signaling pathways, particularly the fibroblast growth factor (FGF)/FGF receptor (FGFR) axis, the platelet-derived growth factor (PDGF) pathway, WNT/β-catenin signaling, and members of the TGFβ superfamily (including TGFβ, BMPs, Activin A). These pathways are critical for wound healing, tissue repair, and the maintenance of tissue homeostasis, but their dysregulation can lead to pathological conditions such as fibrosis and cancer[1][2][4][5][6][8]. In cancer and fibrotic diseases, the abnormal activation of fibroblast proliferation may promote an environment conducive to disease progression by enhancing extracellular matrix deposition, secretory activity, and immunomodulation[3][7]. The term does not designate a single pharmacological target, but rather describes the outcome of complex signaling networks. Key pathways involved in fibroblast proliferation: - Fibroblast growth factors (FGFs) and FGF receptors (FGFRs): Canonical FGF signaling is pivotal in stimulating fibroblast division; after FGF binds FGFR, downstream pathways such as RAS/MAPK, PI3K/AKT, and PLCγ are activated, leading to gene expression changes that drive proliferation and survival[2][4][6][8][10]. - TGFβ superfamily: TGFβ, BMPs, and Activin A can either promote or inhibit fibroblast proliferation and differentiation depending on the tissue and context[1]. - PDGF pathway: PDGF acts as a mitogenic signal for fibroblasts, particularly in wound healing and fibrotic conditions[1]. - WNT pathway: WNT proteins secreted by fibroblasts and other cells regulate both fibroblast and epithelial cell proliferation, contributing to niche maintenance (e.g., in intestinal crypts)[5]. Therapeutic note: While the promotion of fibroblast proliferation as a process is not a direct drug target, specific proteins involved in this process—such as FGFRs or TGFβ receptors—are established therapeutic targets; agents modulating these targets are being researched for fibrosis, cancer, and regenerative applications[2][4][6][8]. The term "fibroblast proliferation promotion" is therefore overly broad and not a valid canonical target.